9:01 PM
 | 
Jan 03, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pfizer discontinues Phase IIb of S. aureus vaccine

9:01 PM
Jan 03, 2019
by Brian Moy
Text Size A A A
Print Print
PDF PDF

Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients undergoing elective spinal fusion surgery after an interim analysis by an IDMC concluded that the S. aureus vaccine composed of four antigens had a low...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review
Sign Up

Article Purchase

$35 USD
More Info >